reported no meaningful difference in hormone levels, with median GH 9.5 ng/mL in patients with cancer compared to 10.4 ng/mL in those without (p=0.981), and IGF-1–738 ng/mL vs. 864 ng/mL (p=0.368). This evidence concerns the gene GH1 and cancer.